EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century

Annals of Oncology

Volumn 14, Issue SUPPL.5, 2003, Pages

  Coleman, M P ^a   Gatta, G ^b   Verdecchia, A ^c   Esteve J ^d   Sant, M ^b   Storm, H H ^e   Allemani, C ^b   Ciccolallo, L ^b   Santaquilani, M ^c   Berrino, F ^b   Oberaigner, W ^f   Jechova, M ^g   Rousarova, M ^g   Aareleid, T ^h   Hakulinen, T ⁱ   Hedelin G ^j   Tron, I ^k   Le Gall, E ^k   Launoy, G ^l   Mace Lesec'h J ^m   Faivre, J ⁿ   Chaplain, G ^o   Carli, P M ^p   Danzon, A ^q   Tretarre, B ^r   Colonna, M ^s   Lacour, B ^t   Raverdy, N ^u   Berger, C ^v   Freycon, F ^v   Grosclaude, P ^w   Kaatsch, P ^x   Ziegler, H ^y   Holzel D ^z   Schubert Fritschle, G ^z   Tryggvadottir, L ^aa   Baili, P ^b   Micheli, A ^b   Taussig, E ^b   Capocaccia, R ^c   Carrani, E ^c   De Angelis, R ^c   Hartley, S ^c   Roazzi, P ^c   Tavilla, A ^c   Valente, F ^c   Ferretti, S ^ab   Crosignani, P ^b   Contiero, P ^b   Conti, E ^ac   Vercelli, M ^ad   Pannelli, F ^ae   Vitarelli, S ^ae   Mosciatti, P ^af   Federico, M ^ag   Artioli, M E ^ag   Ponz De Leon, M ^ah   Benatti, P ^ah   De Lisi, V ^ai   Serventi, L ^ai   Zanetti, R ^aj   Patriarca, S ^aj   Magnani, C ^ak   Pastore, G ^ak   Gafa L ^al   Tumino, R ^al   Falcini, F ^am   Budroni, M ^an   Paci, E ^ao   Crocetti, E ^ao   Zambon, P ^ap   Guzzinati, S ^ap   Dalmas, M ^aq   Langmark, F ^ar   Andersen, A ^ar   Rachtan, J ^as   Bielska Lasota, M ^at   Wronkowski, Z ^at   Zwierko, M ^at   Pinheiro, P S ^au   Plesko I ^av   Obsitnikova A ^av   Pompe Kirn, V ^aw   Izarzugaza, I ^ax   Martinez Garcia, C ^ay   Garau, I ^az   Navarro, C ^ba   Chirlaque, M D ^ba   Ardanaz, E ^bb   Moreno, C ^bb   Galceran, J ^bc   Torrella, A ^bd   Peris Bonet, R ^be   Barlow, L ^bf   Moller T ^bf   Jundt, G ^bg   Lutz, J M ^bh   Usel, M ^bh   Coebergh, J W W ^bi   Van Der Does Van Den Berg, A ^bj   Visser, O ^bk   Godward, S ^bl   Williams, E M I ^bm   Forman, D ^bn   Quinn, M J ^bo   Roche, M ^bp   Edwards, S ^bp   Stiller, C ^bq   Verne, J ^br   Moller H ^bs   Bell, J ^bs   Botha, J L ^bt   Lawrence, G ^bu   Black, R ^bv   Brewster, D ^bv   Steward, J A ^bw   more..

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITÉ LYON 1   (France)

^e DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^f Tyrol Cancer Registry   (Austria)

^g Institute of Health Information and Statistics of the Czech Republic   (Czech Republic)

^h Estonian Cancer Registry   (Estonia)

ⁱ FINNISH CANCER REGISTRY   (Finland)

^j Cancer Registry of Bas Rhin   (France)

^k Bretagne Childhood Cancer Registry   (France)

^l Calvados Digestive Cancer Registry   (France)

^m Calvados General Cancer Registry   (France)

ⁿ ote d'Or Digestive Cancer Registry   (France)

^o Côte d'Or Gynaecological Cancer Registry   (France)

^p ote d'Or Malignant Haemopathies Registry   (France)

^q Doubs Cancer Registry   (France)

^r Herault Cancer Registry   (France)

^s Is ere Cancer Registry   (France)

^t Lorraine Childhood Cancer Registry   (France)

^u Somme Cancer Registry   (France)

^v Rhone Alpes Childhood Registry   (France)

^w Tarn Cancer Registry   (France)

^x German Childhood Cancer Registry   (Germany)

^y SAARLAND CANCER REGISTRY   (Germany)

^z Munich Cancer Registry   (Germany)

^aa ICELANDIC CANCER REGISTRY   (Iceland)

^ab Ferrara Cancer Registry   (Italy)

^ac Latina Cancer Registry   (Italy)

^ad Ligurian Region Cancer Registry   (Italy)

^ae Macerata Cancer Registry   (Italy)

^af Marche Childhood Cancer Registry   (Italy)

^ag MODENA CANCER REGISTRY   (Italy)

^ah Marche Childhood Cancer Registry ^*  (Italy)

^ai PARMA CANCER REGISTRY   (Italy)

^aj Center for Epidemiology and Prevention in Oncology   (Italy)

^ak Piedmont Childhood Cancer Registry   (Italy)

^al Ragusa Cancer Registry   (Italy)

^am Romagna Cancer Registry   (Italy)

^an Sassari Cancer Registry   (Italy)

^ao Tuscan Cancer Registry   (Italy)

^ap Venetian Cancer Registry   (Italy)

^aq Malta National Cancer Registry   (Malta)

^ar CANCER REGISTRY OF NORWAY   (Norway)

^as Cracow Cancer Registry   (Poland)

^at INSTITUTE OF ONCOLOGY   (Poland)

^au Southern Portugal Cancer Registry   (Portugal)

^av National Cancer Registry of   (Slovakia)

^aw INSTITUTE OF ONCOLOGY   (Slovenia)

^ax Basque Country Cancer Registry   (Spain)

^ay Granada Cancer Registry   (Spain)

^az Mallorca Cancer Registry   (Spain)

^ba Murcia Cancer Registry   (Spain)

^bb Navarra Cancer Registry   (Spain)

^bc Tarragona Cancer Registry   (Spain)

^bd Childhood Tumour Registry of Valencia   (Spain)

^be National Registry of Childhood Tumours   (Spain)

^bf Cancer Registry of Sweden   (Sweden)

^bg Cancer Registry of Basel   (Switzerland)

^bh GENEVA CANCER REGISTRY   (Switzerland)

^bi Eindhoven Cancer Registry   (Netherlands)

^bj Dutch Childhood Oncology Group   (Netherlands)

^bk Cancer Center Amsterdam   (Netherlands)

^bl East Anglian Cancer Registry   (United Kingdom)

^bm Merseyside and Cheshire Cancer Registry   (United Kingdom)

^bn Northern and Yorkshire Cancer Registry and Information Service   (United Kingdom)

^bo OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

^bp UNIVERSITY OF OXFORD   (United Kingdom)

^bq Childhood Cancer Research Group   (United Kingdom)

^br Oxford Center Intelligence Unit ^*  (United Kingdom)

^bs Thames Cancer Registry   (United Kingdom)

^bt Trent Cancer Registry   (United Kingdom)

^bu W Midlands Cancer Intelligence Unit   (United Kingdom)

^bv Cancer Information Group   (United Kingdom)

^bw Welsh Cancer Intelligence and Surveillance Unit   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; COLON CANCER; EUROPE; HEALTH PROGRAM; HUMAN; LUNG CANCER; MELANOMA; ONSET AGE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; RECTUM CANCER; SEX DIFFERENCE; STOMACH CANCER; TESTIS CANCER; UTERINE CERVIX CANCER; AGE; BREAST TUMOR; CHILD; COLON TUMOR; FEMALE; LUNG TUMOR; MALE; MORTALITY; NEOPLASM; PROSTATE TUMOR; REGISTER; SKIN TUMOR; STATISTICS; STOMACH TUMOR; SURVIVAL; SURVIVAL RATE; TESTIS TUMOR; UTERINE CERVIX TUMOR;

AGE FACTORS; BREAST NEOPLASMS; CHILD; COLONIC NEOPLASMS; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; REGISTRIES; SEX FACTORS; SKIN NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TESTICULAR NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 2342530749     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdg756     Document Type: Article

References (94)

1. Ferlay J, Bray F, Sankila R, Parkin DM. EUCAN: cancer incidence, mortality and prevalence in the European Union, version 2.0. [on-line] www.iarc.fr. IARC CancerBase No. 4. Lyon, France: IARC 1999.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. [on-line] www.iarc.fr. IARC CancerBase No. 5. Lyon, France: IARC 2001.
3. Micheli A, Mugno E, Krogh V et al. Cancer prevalence in European registry areas. Ann Oncol 2002; 13: 840-865.
4. Capocaccia R, Gatta G, Roazzi P et al. and the EUROCARE Working Group. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 2003; 14 (Suppl 5): v14-v27.
5. Jensen OM, Parkin DM, MacLennan R et al. (eds): Cancer Registration: Principles and Methods. IARC Scientific Publications No. 95. Lyon, France: IARC 1991.
6. Doll R, Payne P, Waterhouse JAH (eds): Cancer Incidence in Five Continents: a Technical Report. Geneva, Switzerland: UICC 1968.
7. Parkin DM, Whelan SL, Ferlay J et al. (eds): Cancer Incidence in Five Continents, volume VII. IARC Scientific Publications No. 143. Lyon, France: IARC 1997.
8. Berrino F, Sant M, Verdecchia A et al. (eds) Survival of cancer patients in Europe: the EUROCARE study. IARC Scientific Publications No. 132. Lyon, France: IARC 1995.
9. Berrino F, Capocaccia R, Estève J et al. (eds): Survival of Cancer Patients in Europe: the EUROCARE-2 Study. IARC Scientific Publications No. 151. Lyon, France: IARC 1999.
10. Sant M, Capocaccia R, Coleman MP et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001; 37: 1659-1667.
11. EUROCARE Working Group. Publications from the EUROCARE study. [on-line] http://www.lshtm.ac.uk/ncdeu/eurocarepublications/
12. Sant M. Differences in stage and therapy for breast cancer across Europe. The EUROCARE Working Group. Int J Cancer 2001; 93: 894-901.
13. Gatta G, Capocaccia R, Sant M et al. Understanding variations in colorectal cancer survival in Europe: a EUROCARE high-resolution study. Gut 2000; 47: 533-538.
14. Sant M, Allemani C, Capocaccia R et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 2003; 106: 416-422.
15. Terracini B, Coebergh JW, Gatta G et al. Childhood cancer survival in Europe: an overview. Eur J Cancer 2001; 37: 810-816.
16. Capocaccia R, Gatta G, Magnani C et al. Childhood cancer survival in Europe 1978-92: the EUROCARE study. Eur J Cancer 2001; 37: 671-816.
17. Coleman MP, Babb P, Damiecki P et al. Cancer survival trends in England and Wales 1971-1995: deprivation and NHS region. Series SMPS No. 61. London, UK: HMSO 1999.
18. Engeland A, Haldorsen T, Dickman PW et al. Relative survival of cancer patients: a comparison between Denmark and other Nordic countries. Acta Oncol 1998; 37: 49-59.
19. Estève J, De Angelis G, Verdecchia A. Trends in cancer survival probability over the period 1978-89. In Berrino F, Capocaccia R, Estève J et al. (eds): Survival of Cancer Patients in Europe: the EUROCARE-2 Study. IARC Scientific Publications No. 151. Lyon, France: IARC 1999; 543-567.
20. Vercelli M, Quaglia A, Casella C et al. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1999; 34: 2264-2270.
21. Micheli A, Mariotto A, Giorgi Rossi A et al. The prognostic role of gender in survival of adult cancer patients. The EUROCARE Working Group. Eur J Cancer 1998; 34: 2271-2278.
22. Gatta G, Capocaccia R, Coleman MP et al. Toward a comparison of survival in American and European cancer patients. Cancer 2000; 89: 893-900.
23. Gatta G, Capocaccia R, Coleman MP et al. Childhood cancer survival in Europe and the USA. Cancer 2002; 95: 1767-1772.
24. Storm H. Survival of adult patients with cancer of soft tissues or bone in Europe. The EUROCARE Working Group. Eur J Cancer 1998; 34: 2212-2217.
25. Jiong L, Berrino F, Coebergh JW. Variation in survival for adults with nasopharyngeal cancer in Europe, 1978-1989. The EUROCARE Working Group. Eur J Cancer 1998; 34: 2162-2166.
26. Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. The EUROCARE Working Group. Eur J Cancer 1998; 34: 2154-2161.
27. Verdecchia A, Mariotto A, Gatta G et al. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003; 39: 1603-1609.
28. Janssen-Heijnen MLG, Gatta G, Forman D et al. Variation in survival of patients with lung cancer in Europe, 1985-89. The EUROCARE Working Group. Eur J Cancer 1998; 34: 2191-2196.
29. Haward R. Making and monitoring cancer policy in the United Kingdom: the cancer registry contribution. In Parkin DM (ed.): Cancer Registries in Evaluation of Clinical Care. IARC Technical Report. Lyon, France: IARC 2002.
30. Cooper Y. Cancer. Commons Hansard, 20 July; 372: c718W. [on-line] http://www.publications.parliament.uk/pa/cm200102/cmhansrd/vo010720/text/ 10720w66.htm10720w66.html_sbhdl (30 June 2003, date last accessed). London, UK: HMSO, 2001.
31. Department of Health. The NHS Cancer Plan. [on-line] http://www.doh.gov. uk/cancer. London, UK: Department of Health 2000.
32. Kerr D, Bevan H, Gowland B et al. Redesigning cancer care. Br Med J 2002; 324: 164-166.
33. National Board of Health. National Cancer Plan, Report 2: Epidemiology. Copenhagen, Denmark: National Board of Health 2000.
34. Berrino F, Micheli A, Sant M, Capocaccia R. Interpreting survival differences and trends. Tumori 1997; 83: 9-16.
35. Norges Offentlige Utredninger. Care and Knowledge: the Norwegian Cancer Plan 1997 [Omsorg og Kunnskap! Norsk kreftplan 1997]. Oslo, Norway: Statens trykning 1997.
36. Verdecchia A, De Angelis R, Capocaccia R et al. The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998; 77: 322-329.
37. Micheli A, Capocaccia R, Martinez-Garcia C et al. Cancer control in Europe: a proposed set of European Cancer Health Indicators. Eur J Public Health 2003; 13: 116-118.
38. Cutler SJ (ed.): International Symposium on End Results of Cancer Therapy. NCI Monograph 15. Bethesda, MD: National Cancer Institute 1964.
39. Comber H. The Irish National Cancer Registry. Ir Med J 1994; 87: 126-128.
40. Organisation for Economic Co-operation and Development. OECD Health Data 2002. 4th edition. Paris, France: OECD 2002
41. Sant M. Overview of EUROCARE-2 results on survival of cancer patients diagnosed 1985-89. In Berrino F, Capocaccia R, Estève J et al. (eds): Survival of Cancer Patients in Europe: the EUROCARE-2 Study. The EUROCARE Working Group. IARC Scientific Publications No. 151. Lyon, France: IARC 1999; 525-541.
42. Evans BT, Pritchard C. Cancer survival rates and GDP expenditure on health: a comparison of England and Wales and the USA, Denmark, Netherlands, Finland, France, Germany, Italy, Spain and Switzerland in the 1990s. Public Health 2000; 114: 336-339.
43. Micheli A, Coebergh JW, Mugno E et al. and the EUROCARE Working Group. European health systems and cancer care. Ann Oncol 2003; 14 (Suppl 5): v41-v60.
44. European Network of Cancer Registries. EUROCIM, version 4.0. Lyon, France: European Network of Cancer Registries 1995.
45. Cutler SJ, Ederer F. Maximum utilisation of the life table method in analyzing survival. J Chron Dis 1958; 8: 699-712.
46. Ederer F, Axtell LM, Cutler SJ. The relative survival: a statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-121.
47. Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chron Dis 1977; 30: 585-597.
48. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 38: 933-942.
49. Micheli A, Baili P, Quinn M et al. and the EUROCARE Working Group. Life expectancy and cancer survival in the EUROCARE-3 cancer registry areas. Ann Oncol 2003; 14 (Suppl 5): v28-v40.
50. Estève J, Benhamou E, Raymond L. Statistical Methods in Cancer Research, volume IV. Descriptive Epidemiology. IARC Scientific Publications No. 128. Lyon, France: IARC 1994.
51. Sant M, Aareleid T, Berrino F et al. and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Ann Oncol 2003; 14 (Suppl 5): v61-v118.
52. Roazzi P, Capocaccia R, Santaquilani M, Carrani E and the EUROCARE Working Group. Electronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol 2003; 14 (Suppl 5): v150-v155.
53. Europe against Cancer. European Code Against Cancer, 3rd edition. [on-line] http://www.cancercode.org/code_12.htm (3 September, 2003; date last accessed).
54. Peckham M, Pinedo HM, Veronesi U (eds): Oxford Textbook of Oncology. Oxford, UK: OUP 1995.
55. Storm H, Dickman PW, Engeland A et al. Do morphology and stage explain the inferior lung cancer survival in Denmark? Eur Respir J 1999; 13: 430-435.
56. Monnet E, Faivre J, Raymond L, Garau I. Influence of stage at diagnosis on survival differences for rectal cancer in three European populations. Br J Cancer 1999; 81: 463-468.
57. MacKie R, Hole D. Audit of public education campaign to encourage earlier detection of malignant melanoma. Br Med J 2003; 304: 1012-1015.
58. US Department of Health and Human Services. National Cancer Institute, Surveillance, Epidemiology and End Results Program. SEER Cancer Statistics Review, 1973-1999 [Dataset on CD-ROM]. Bethesda, MD: US Department of Health and Human Services 2001.
59. Sankaranarayanan R, Black RJ, Parkin DM (eds): Cancer Survival in Developing Countries. IARC Scientific Publications No. 145. Lyon, France: IARC 1998.
60. Freeman HP, Reuben SH. Voices of a broken system: real people, real problems. President's Cancer Panel: Report of the Chairman 2000-2001. Washington, DC: National Cancer Institute 2002.
61. McDavid K, Tucker T, Sloggett A, Coleman MP. Cancer survival in Kentucky and health insurance coverage. Arch Intern Med 2003; 163: 2135-2144.
62. Peto R, Boreham J, Clarke M et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
63. Coleman MP, Babb P, Stockton D et al. Breast cancer incidence, survival and mortality trends in England and Wales. Lancet 2000; 356: 590-591.
64. Quinn MJ, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. UK Association of Cancer Registries. Br Med J 1995; 311: 1391-1393.
65. Blanks RG, Moss SM, McGahan CE et al. Effect of NHS Breast Screening Programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. Br Med J 2000; 321: 665-669.
66. Martijn H, Voogd AC, van de Poll-Franse LV et al. Improved survival of patients with rectal cancer since 1980: a population-based study. Eur J Cancer 2003; 39: 2073-2079.
67. Mitry E, Bouvier A-M, Estève J, Faivre J. Benefit of operative mortality reduction on colorectal cancer survival. Br J Surg 2002; 89: 1557-1562.
68. Evans HS, Møller H. Recent trends in prostate cancer incidence and mortality in southeast England. Eur Urol 2003; 43: 337-341.
69. Horninger W, Reissigl A, Rogatsch H et al. Prostate cancer screening in Tyrol, Austria: experience and results. Eur Urol 1999; 35: 523-538.
70. Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002; 38: 99-166.
71. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131-1135.
72. Berrino F, Estève J, Coleman MP. Basic issues in the estimation and comparison of cancer patient survival. In Berrino F, Sant M, Verdecchia A et al. (eds): Survival of Cancer Patients in Europe: the EUROCARE Study. IARC Scientific Publications No. 132. Lyon, France: IARC 1995; 1-14.
73. Berrino F. The EUROCARE Study: strengths, limitations and perspectives of population-based, comparative survival studies. Ann Oncol 2003; 14 (Suppl 5): v9-v13.
74. Bullard J, Coleman MP, Robinson D et al. Completeness of cancer registration: a new method for routine use. Br J Cancer 2000; 82: 1111-1116.
75. Robinson D, Bell J, Møller H. Comparing survival rates between different registries can be difficult. Br Med J 2000; 321: 1227a.
76. Stotter A, Bright N, Silcocks P, Botha JL. Effect of improved data collection on breast cancer incidence and survival: reconciliation of a registry with a clinical database. Br Med J 2000; 321: 214.
77. Cookson JB. Cancer survival. Lancet 2000; 356: 1611.
78. Ravi S. But can we rely on the statistics? Br Med J 1999; 318: 1163.
79. Moran T, Collins S, Gibbs A, Woodman CBJ. Survival of patients with colon cancer in Europe: a cautionary tale. Colorect Dis 2000; 2: 190-192.
80. Prior P, Woodman CB, Wilson S, Threlfall AG. Reliability of underlying incidence rates for estimating the effect and efficiency of screening for breast cancer. J Med Screen 1996; 3: 119-122.
81. Woodman CBJ, Gibbs A, Scott N et al. Are differences in stage at presentation a credible explanation for reported differences in the survival of patients with colorectal cancer in Europe? Br J Cancer 2001; 85: 787-790.
82. Sant M, Gatta G, Valente F et al. The ITACARE study. Tumori 1997; 83: 17-24.
83. MacKie R, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. Br Med J 1996; 312: 1125-1128.
84. Scottish Cancer Intelligence Unit. Trends in cancer survival in Scotland 1971-1995. Edinburgh, UK: Information and Statistics Division 2000.
85. Gatta G, Sant M, Coebergh JW, Hakulinen T. Substantial variation in therapy for colorectal cancer across Europe: EUROCARE analysis of cancer registry data for 1987. The EUROCARE Working Group. Eur J Cancer 1996; 32A: 831-835.
86. Kogevinas M, Porta M. Socioeconomic differences in cancer survival: a review of the evidence. In Kogevinas M, Pearce N, Susser M et al. (eds): Social Inequalities and Cancer. IARC Scientific Publications No. 138. Lyon, France: IARC 1997; 177-206.
87. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 2975-2978.
88. Irwig L, Armstrong B. EUROCARE-2: relevance for assessment of quality of cancer services? Lancet 2000; 355: 427-428.
89. Feuer EJ, Merrill JA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer. Part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1025-1032.
90. Coleman MP, Evans BG, Barrett G. Confidentiality and the public interest in medical research-will we ever get it right? Clin Med 2003; 3: 219-228.
91. Riikliku Statistika Seadus [National Statistics Act]. Riigi Teataja I, 1997, 51, 822.
92. De Angelis R, Capocaccia R, Hakulinen T et al. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999; 18: 441-454.
93. Forman D, Stockton D, Møller H et al. Cancer prevalence in the United Kingdom: results from the EUROPREVAL study. Ann Oncol 2003; 14: 648-654.
94. Capocaccia R, Colonna M, Corazziari I et al. Measuring cancer prevalence in Europe: the EUROPREVAL project. Ann Oncol 2002; 13: 831-849.